Potential Roles for Metformin and Everolimus in Obese Women With ER-Positive Breast Cancer

Get Permission

Obesity increases the risk of breast cancer death in postmenopausal women with estrogen receptor (ER)-positive breast cancer, although underlying mechanisms remain unclear. In studies reported in the Journal of the National Cancer Institute, Fuentes-Mattei and colleagues identified an association of obesity with 59 biologic functional changes (P < .05) linked to cancer hallmarks using functional transcriptomic analysis in pretreatment biopsies from a prospective cohort of 137 ER-positive breast cancer patients. Gene enrichment analysis showed significant enrichment of AKT target genes (P = .04) and epithelial-mesenchymal transition genes (P = .03).

Investigation in obese mouse models showed activation of the AKT/mTOR pathway in obesity-accelerated mammary tumor growth (3.7- to 7.0-fold, P < .001). Treatment with metformin or everolimus (Afinitor) suppressed obesity-induced secretion of adipokines and breast tumor formation and growth (0.5-fold, P = .04; 0.3-fold, P < .001).

In a coculture model examining the impact of adipocytes/adipokines on breast cancer cell proliferation, adipocyte-secreted adipokines (eg, TIMP-1) regulated adipocyte-induced proliferation and invasion. Metformin suppressed the adipocyte-induced cell proliferation and adipokine secretion from adipocytes.

The investigators concluded, “Adipokine secretion and AKT/mTOR activation play important roles in obesity-accelerated breast cancer aggressiveness in addition to hyperinsulinemia, estrogen signaling, and inflammation. Metformin and everolimus have potential for therapeutic interventions of ER[-positive] breast cancer patients with obesity.” ■

Fuentes-Mattei E, et al: J Natl Cancer Inst 106(7):dju158, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.